deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03147885

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma

Sponsor: Barbara Ann Karmanos Cancer Institute

Conditions Diffuse Large B-Cell Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Extranodal Marginal Zone Lymphoma Recurrent Follicular Lymphoma Recurrent Indolent Adult Non-Hodgkin Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Waldenstrom Macroglobulinemia Refractory B-Cell Non-Hodgkin Lymphoma Refractory Extranodal Marginal Zone Lymphoma Refractory Follicular Lymphoma Refractory Mantle Cell Lymphoma Stage III Non-Hodgkin Lymphoma Stage IV Non-Hodgkin Lymphoma Transformed Recurrent Non-Hodgkin Lymphoma
Interventions Selinexor
Updated 15 times since 2017 Last updated: Sep 23, 2025 Started: Jun 20, 2017 Primary completion: Dec 31, 2027 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Diffuse Large B-Cell Lymphoma and Recurrent B-Cell Non-Hodgkin Lymphoma and is currently ongoing. Barbara Ann Karmanos Cancer Institute leads this study, which shows 15 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Mar 2018 · 8 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Jan 2021 · 22 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Mar 2023 · 13 months · monthly snapshot~Mar 2023 – ~Apr 2024 · 13 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Oct 2025 · 5 months · monthly snapshot~Oct 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded

  1. Oct 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  2. May 2025 — Oct 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Sep 2024 — May 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Mar 2023 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Feb 2022 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Sep 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Mar 2019 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jul 2017 — Mar 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Jun 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Barbara Ann Karmanos Cancer Institute
  • National Cancer Institute (NCI)
Data source: Barbara Ann Karmanos Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations